Results 251 to 260 of about 10,846,120 (403)

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

open access: yesMolecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert   +13 more
wiley   +1 more source

Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients.

open access: yesBritish Journal of Clinical Pharmacology, 2015
M. Schleibinger   +7 more
semanticscholar   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

High throughput screening for the design of protein binding polymers. [PDF]

open access: yesChem Sci
Bapp C   +5 more
europepmc   +1 more source

Estrogen-binding Proteins

open access: yesFolia Endocrinologica Japonica, 1968
Hiroo Takikawa, Sachiko Yoshinaga
openaire   +4 more sources

Home - About - Disclaimer - Privacy